提示: 手机请竖屏浏览!

针对B群脑膜炎奈瑟菌的4CMenB疫苗既有好消息也有坏消息
Good News and Bad News — 4CMenB Vaccine for Group B Neisseria meningitidis


Lee H. Harrison ... 其他 • 2020.01.23

在全球范围内,脑膜炎奈瑟菌仍然是脑膜炎、脓毒症和其他严重感染的主要致病原因。几乎所有脑膜炎球菌感染均由根据多糖荚膜生化成分分类的6个血清群(A、B、C、W、X和Y群)之一引起。在过去20年间,我们应用脑膜炎球菌荚膜多糖-蛋白结合疫苗在预防侵袭性脑膜炎球菌病方面取得了重大成功。例如“非洲脑膜炎带”(African meningitis belt)(从塞内加尔到埃塞俄比亚)引入单价A群脑膜炎球菌荚膜结合疫苗,英国引入C群脑膜炎球菌结合疫苗之后,基本上消除了由这些血清群引起的侵袭性脑膜炎球菌病负担1,2





作者信息

Lee H. Harrison, M.D., and David S. Stephens, M.D.
From the Infectious Diseases Epidemiology Research Unit, School of Medicine and Graduate School of Public Health, University of Pittsburgh, Pittsburgh (L.H.H.); and the Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, and Woodruff Health Sciences Center, Emory University, Atlanta (D.S.S.).

 

参考文献

1. Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. Lancet Infect Dis 2017;17:867-872.

2. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17:840-847.

3. Harrison LH. Vaccines for prevention of group B meningococcal disease: not your father’s vaccines. Vaccine 2015;33:Suppl 4D32-D38.

4. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015;64:1171-1176.

5. Stephens DS. Boosters for meningococcal B vaccines? Lancet Infect Dis 2017;17:4-6.

6. Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med 2020;382:309-317.

7. Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet 2016;388:2775-2782.

8. Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med 2020;382:318-327.

9. Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384:2123-2131.

10. McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak — Oregon, 2015-2016. J Infect Dis 2017;216:1130-1140.

11. Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college — Rhode Island, 2015-2016. Clin Infect Dis 2017;64:1115-1122.

12. Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-743.

服务条款 | 隐私政策 | 联系我们